Investigational new drugs
Journal
Overview
publication venue for
-
Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).
2010
-
Blackberry-induced hand-foot skin reaction to sunitinib.
2008
-
Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity.
2007
-
Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.
1990
-
A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia..
40.
2022
-
A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma..
40.
2021
-
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers..
39.
2021
-
A decision process for drug discovery in retinoblastoma..
39.
2020
-
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma..
38.
2020
-
A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma..
37.
2019
-
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors..
38.
2019
-
A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor..
37.
2018
-
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors..
36.
2018
-
A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer..
36.
2018
-
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies..
36.
2018
-
Repurposing of the CDK inhibitor PHA-767491 as a NRF2 inhibitor drug candidate for cancer therapy via redox modulation..
36.
2018
-
A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma..
36.
2017
-
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel..
35.
2017
-
Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors..
35.
2017
-
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors..
35.
2016
-
A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma..
34.
2016
-
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors..
34.
2016
-
Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors..
33.
2015
-
A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer..
33.
2015
-
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors..
33.
2014
-
A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors..
33.
2014
-
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma..
32.
2014
-
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer..
32.
2014
-
A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer..
32.
2014
-
Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach..
32.
2014
-
A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma..
32.
2013
-
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner..
31.
2013
-
A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors..
31.
2013
-
Using the neurotransmitter serotonin to target imaging agents to glioblastoma cells..
30.
2012
-
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma..
31.
2012
-
A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer..
31.
2012
-
A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer..
31.
2012
-
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer..
31.
2012
-
Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer..
30.
2012
-
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies..
30.
2011
-
Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma..
30.
2011
-
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors..
30.
2011
-
A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors..
30.
2011
-
Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma..
30.
2011
-
Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium..
30.
2010
-
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma..
30.
2010
-
A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer..
29.
2010
-
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma..
29.
2010
-
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors..
29.
2010
-
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer..
29.
2010
-
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma..
29.
2010
-
Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors..
28.
2009
-
Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience..
28.
2009
-
Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer..
28.
2009
-
Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer..
27.
2008
-
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia..
26.
2008
-
Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma..
26.
2007
-
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor..
26.
2007
-
Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors..
25.
2007
-
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors..
25.
2007
-
Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma..
25.
2006
-
A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma..
24.
2006
-
A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers..
25.
2006
-
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane..
24.
2006
-
Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients..
24.
2006
-
Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)..
22.
2004
-
Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors..
22.
2004
-
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum..
22.
2004
-
Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041)..
22.
2004
-
Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma..
21.
2003
-
Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma..
21.
2003
-
Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma..
20.
2002
-
A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck..
20.
2002
-
Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma..
19.
2001
-
Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma..
18.
2000
-
Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors..
18.
2000
-
A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma..
16.
1998
-
A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors..
15.
1997
-
A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma..
15.
1997
-
Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma..
14.
1996
-
Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors..
13.
1995
-
Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas..
12.
1994
-
Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma..
12.
1994
-
Phase II trial of topotecan in patients with advanced renal cell carcinoma..
12.
1994
-
A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer..
11.
1993
-
Phase II trial of gallium nitrate in previously treated patients with small cell lung cancer..
11.
1993
-
A phase II trial of CI-921 in advanced malignancies..
10.
1992
-
Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT..
10.
1992
-
Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma..
10.
1992
-
Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma..
10.
1992
-
Menogaril in the treatment of malignant mesothelioma: a phase II study..
10.
1992
-
Phase II trial of esorubicin (4'deoxydoxorubicin, DxDx) in patients with small cell lung cancer..
9.
1991
-
Phase II trial of N-methylformamide in patients with metastatic melanoma..
9.
1991
-
Phase II trial of cisplatin and etoposide in patients with metastatic melanoma..
9.
1991
-
4'-EPI-doxorubicin in advanced lung cancer. A phase II trial..
8.
1990
-
Phase II trial of Didemnin B in patients with advanced renal cell carcinoma..
8.
1990
-
Phase II trial of carboplatin and vinblastine in adenocarcinoma of the stomach..
8.
1990
-
Phase II trial of carboplatin in patients with advanced melanoma..
8.
1990
-
Phase II study of CHIP chemotherapy in advanced adenocarcinomas of the upper gastrointestinal tract..
8.
1990
-
A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma..
6.
1988
-
Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity..
6.
1988
-
Phase II trial of 10 deaza-aminopterin in patients with bladder cancer..
4.
1986
-
Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.
2013
-
The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.
2013
-
The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.
2011
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)